公开(公告)号：EP3835321A1

公开(公告)日：2021-06-16

申请号：EP19847615.2

申请日：2019-08-09

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： IGAWA, Tomoyuki ,  SAKURAI, Mika ,  SHIMIZU, Shun ,  HORI, Yuji ,  HIRONIWA, Naoka ,  SAVORY, Nasa ,  NARITA, Yoshinori ,  KAMIKAWA, Takayuki ,  MIYAZAKI, Taro ,  KADONO, Shojiro ,  HASEGAWA, Masami ,  TATSUMI, Kanako ,  HAYASAKA, Akira ,  KAWAI, Takeaki ,  MIMOTO, Futa ,  KAWAUCHI, Hiroki ,  KAMIMURA, Masaki

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K47/64 ,  A61K47/68 ,  A61P35/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/13 ,  C12N15/63 ,  C12P21/08

摘要： An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same.
Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided.
The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.

公开(公告)号：EP4410308A1

公开(公告)日：2024-08-07

申请号：EP22876287.8

申请日：2022-09-28

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： ISHII, Shinya ,  KAMIKAWA, Takayuki ,  KIMURA, Naoki ,  KODAMA, Tatsushi

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61P43/00

CPC分类号： A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07K16/28 ,  A61K39/464402 ,  A61K39/461

摘要： The present disclosure provides anticancer agents containing a multispecific antigen-binding molecule that can efficiently and specifically recruit T cells to the target cancer cells, particularly CLDN6-expressing cancer cells and such, and can treat cancer through the cytotoxic activity of T cells against target cancer tissues containing CLDN6-expressing cells; combination therapies using the anticancer agent and at least one other anticancer agent; and pharmaceutical compositions for use in the combination therapies.

公开(公告)号：EP3997230A1

公开(公告)日：2022-05-18

申请号：EP20837625.1

申请日：2020-07-10

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： KIMURA, Naoki ,  KODAMA, Tatsushi ,  ISHII, Shinya ,  MURAOKA, Masaru ,  KAMIKAWA, Takayuki

IPC分类号： C12N15/13